ENESDENewsletter →
Shotlee
Get the app
📖Complete Guide✅Updated 2026🔬Evidence-Based

Egrifta (Tesamorelin) Guide

Dosing & Fat Loss 2026

Complete guide to Egrifta (Tesamorelin). Understand how this FDA-approved GHRH peptide targets visceral fat, proper dosing protocols, and side effects.

Download on theApp Store
Get it onGoogle Play
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
EgriftaB12
EGRIFTA
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Egrifta
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
EgriftaRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
EgriftaB12
EGRIFTA
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Egrifta
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
EgriftaRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

FDA-Approved Visceral Fat Reduction

Egrifta (generic name Tesamorelin) is an FDA-approved growth hormone-releasing hormone (GHRH) analogue. Originally approved specifically to reduce excess abdominal fat (lipodystrophy) in HIV patients, it is now widely utilized off-label for aggressive visceral fat reduction and body recomposition.

02DEEP DIVE

What Is Egrifta (Tesamorelin) Guide?

Egrifta (generic name Tesamorelin) is an FDA-approved growth hormone-releasing hormone (GHRH) analogue. Originally approved specifically to reduce excess abdominal fat (lipodystrophy) in HIV patients, it is now widely utilized off-label for aggressive visceral fat reduction and body recomposition.

Unlike synthetic human growth hormone (hGH), Egrifta stimulates your own pituitary gland to pulse natural growth hormone into the bloodstream, preserving the delicate feedback loop and minimizing tachyphylaxis (receptor burnout).

03MECHANICS

Key Biohacking Mechanics

1
Selectively targets visceral adipose tissue surrounding internal organs
2
Stimulates lipolysis directly at the adipocyte via GH-receptor binding
3
Clinical trials: average 18% reduction in visceral fat within 26 weeks
4
Binds to GHRH receptors in the anterior pituitary
5
Causes pulsatile (natural) GH surges, unlike continuous exogenous GH
6
Increases serum IGF-1 levels for anabolism and recovery
04DEEP DIVE

Dosing Protocol

Injected daily (subcutaneous) for HIV lipodystrophy.

Often used in anti-aging or fitness for body recomp.

Bedtime or morning on empty stomach to maximize GH pulse.

Note: Carbohydrates and insulin flatline GH release. Injecting Egrifta after an insulin-spiking meal renders it virtually useless.

05WHAT TO TRACK

Side Effects & Safety

01
🔬
Common Effects
Injection site reactions (redness, swelling). Joint pain and muscle aches. Peripheral edema (mild water retention). Paresthesia (tingling in extremities)
02
📱
Monitoring Required
May worsen glucose tolerance — monitor fasting glucose. IGF-1 levels should be checked periodically. Discontinue if active malignancy suspected. Not recommended during pregnancy
06WHAT TO TRACK

Vital Protocol FAQs

01
🔬
What is the difference between Egrifta and Egrifta SV?
Egrifta SV (Single Vial) is the newer formulation that achieves the standard 2mg dose using a much smaller volume of sterile water, making the injection faster and less visibly irritating.
02
⚖️
Does it work for subcutaneous fat?
While it primarily excels at shrinking visceral (organ) fat, the systemic increase in GH/IGF-1 will eventually promote the breakdown of standard subcutaneous fat over a 3 to 6-month cycle.
03
🔬
Do you have to cycle Egrifta?
Yes, most practitioners suggest a 5 days on, 2 days off protocol, or cycles lasting 12-16 weeks followed by a 4-week break. This prevents pituitary desensitization.
07FAQ

Guide FAQs

Complete guide to Egrifta (Tesamorelin). Understand how this FDA-approved GHRH peptide targets visceral fat, proper dosing protocols, and side effects.

Yes. Shotlee supports tracking Egrifta doses, side effects, and health metrics. It is free to use.

Free · Always

Track Your Egrifta Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.

Download on theApp Store
Get it onGoogle Play

📚References & sources

🔗Keep exploring

All Guides
→
Trackers
→
Compare
→
Start tracking